| Project/Area Number |
24591627
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MUTO Masahiko 山口大学, 大学院医学系研究科, 教授 (40175625)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKAI Akira 山口大学, 大学院医学系研究科, 教授 (60252516)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | Heat shock factor 1 / Malignant melanoma / Heat shock factor 1：HSF1 / 熱ショック因子 / 悪性黒色腫 / malignant melanoma / heat shock factor 1 / migration / invasion / metastasis |
|---|
| Outline of Final Research Achievements |
Recent studies have reported that heat shock factor 1 (HSF1) supports the malignant phenotype by promoting oncogenic signal transduction pathways, proliferation, survival, protein synthesis and glucose metabolism, suggesting that HSF1 may be a critical driver in cancer and a potential therapeutic target. However, the biological functions of HSF1 in human melanoma remain poorly understood.
We found that HSF1 knockdown led to a marked reduction in migration and invasive ability, and these functions were restored by overexpression of wild-type HSF1. To confirm the in vitro results, we performed subcutaneous xenograft experiments in athymic nude mice. We found that HSF1 was required for melanoma invasion and metastasis, as well as tumorigenic potential in vivo. Overall, these results show that HSF1 is indispensable for melanoma progression and metastasis, and suggests that HSF1 could be a promising therapeutic target for melanoma.
|
